Please sign in to follow a disease.
Intra-immusg Pte Ltd
Clinical trials sponsored by Intra-immusg Pte Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New antibody drug shows promise in fighting advanced cancers Results expected Dec 2026 (estimated)
- New antibody PRL3-Zumab tested against advanced cancers Results expected Dec 2026 (estimated)
- New antibody drug trial offers hope for Hard-to-Treat wet AMD Results expected Feb 2027 (estimated)
-
New antibody drug trial offers hope for Hard-to-Treat wet AMD
Disease control Recruiting nowThis early-phase trial tests a new drug called PRL3-zumab in 15 people with wet age-related macular degeneration (nAMD) who have not improved with standard treatments. The drug is given by IV every two weeks for three doses. The study will check for safety and any signs that visi…
Phase 1/2 • Sponsor: Intra-IMMUSG Pte Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New antibody PRL3-Zumab tested against advanced cancers
Disease control Recruiting nowThis study tests an experimental drug called PRL3-zumab in 52 adults with advanced solid tumors. The drug is given by IV every two weeks. Researchers want to see if it can slow cancer growth and how safe it is. Participants must have had no more than three prior treatments and be…
Phase 2/3 • Sponsor: Intra-IMMUSG Pte Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC